Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Table 4 Risk of second primary malignancies based on the follow-up duration

SPM	Overall SIR (95%CI)	SIR at 6-23 mo follow-up (95%CI)	SIR at > 24 mo follow-up (95%CI)
All sites	1.26 (1.09-1.45)1	1.16 (0.9-1.49)	1.31 (1.1-1.55)1
Solid malignancies	1.15 (0.98-1.35)	1.09 (0.82-1.43)	1.18 (0.97-1.43)
Colorectal	0.66 (0.34-1.15)	0.47 (0.10-1.38)	0.76 (0.35-1.44)
Lung/bronchus	1.31 (0.89-1.86)	1.48 (0.76-2.58)	1.23 (0.74-1.92)
Breast	1.06 (0.68-1.58)	0.91 (0.37-1.88)	1.14 (0.66-1.82)
Prostate	1.11 (0.71-1.65)	1.03 (0.45-2.03)	1.15 (0.66-1.87)
Kidney	2.40 (1.15-4.42)1	0.71 (0.02-3.95)	3.27 (1.5-6.21)1
Hematologic malignancies	2.36 (1.63-3.29)1	2.03 (0.97-3.73)	2.53 (1.62-3.76)1
Lymphoma	1.59 (0.82-2.78)	1.56 (0.42-3.99)	1.61 (0.69-3.17)
Leukemia	3.78 (2.2-6.05)1	3.88 (1.42-8.44)1	3.72 (1.86-6.66)1
AML	7.74 (3.71-14.24)1	9.02 (2.46-23.09)1	7.08 (2.6-15.4)1

¹Indicates a statistically significant value. AML: Acute myeloid leukemia; SIR: Standardized incidence ratio; SPM: Second primary malignancies.